Drug Profile

MIL 108

Alternative Names: BCG-001; MIL-108

Latest Information Update: 01 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Biocytogen; Beijing Mabworks Biotech
Developer Beijing Mabworks Biotech
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD276 protein inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2022 Beijing Mabworks Biotech and Biocytogen agree to co-develop MIL 108 for Solid tumours, before March 2022 (Beijing Mabworks Biotech, March 2022)
28 Mar 2022 Preclinical trials in Solid tumours in China (Parenteral)
28 Mar 2022 Beijing Mabworks Biotech plans to file an IND application for Solid tumours in 2023 (Beijing Mabworks Biotech, March 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com